These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 18001404

  • 1. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
    Kang JM, Kim N, Lee DH, Park YS, Kim YR, Kim JS, Jung HC, Song IS.
    Helicobacter; 2007 Dec; 12(6):623-8. PubMed ID: 18001404
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
    Cheon JH, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS.
    Helicobacter; 2006 Feb; 11(1):46-51. PubMed ID: 16423089
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q, Pan Y, Zhang L, Xiao SD.
    Chin J Dig Dis; 2005 Feb; 6(4):202-5. PubMed ID: 16246231
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.
    Nista EC, Candelli M, Zocco MA, Cazzato IA, Cremonini F, Ojetti V, Santoro M, Finizio R, Pignataro G, Cammarota G, Gasbarrini G, Gasbarrini A.
    Aliment Pharmacol Ther; 2005 May 15; 21(10):1241-7. PubMed ID: 15882245
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.
    Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L.
    Dig Liver Dis; 2010 Feb 15; 42(2):110-4. PubMed ID: 19846355
    [Abstract] [Full Text] [Related]

  • 7. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
    Wang Z, Wu S.
    Singapore Med J; 2012 Apr 15; 53(4):273-6. PubMed ID: 22511052
    [Abstract] [Full Text] [Related]

  • 8. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
    Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS.
    Helicobacter; 2010 Feb 15; 15(1):38-45. PubMed ID: 20302588
    [Abstract] [Full Text] [Related]

  • 9. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
    Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S.
    J Clin Gastroenterol; 2013 Mar 15; 47(3):228-32. PubMed ID: 22858517
    [Abstract] [Full Text] [Related]

  • 10. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.
    Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou YP, Hu ML, Tai WC, Chiu KW, Chiou SS, Wu DC, Hu TH.
    Helicobacter; 2012 Jun 15; 17(3):216-23. PubMed ID: 22515360
    [Abstract] [Full Text] [Related]

  • 11. Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
    Cheon JH, Kim SG, Kim JM, Kim N, Lee DH, Kim JS, Jung HC, Song IS.
    J Gastroenterol Hepatol; 2006 Oct 15; 21(10):1590-5. PubMed ID: 16928222
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A.
    Am J Gastroenterol; 2006 Sep 15; 101(9):1985-90. PubMed ID: 16968503
    [Abstract] [Full Text] [Related]

  • 14. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
    Kung NN, Sung JJ, Yuen NW, Ng PW, Wong KC, Chung EC, Lim BH, Choi CH, Li TH, Ma HC, Kwok SP.
    Am J Gastroenterol; 1997 Mar 15; 92(3):438-41. PubMed ID: 9068464
    [Abstract] [Full Text] [Related]

  • 15. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A, Kadayifci A, Safali M, Ilgan S, Bagci S.
    J Dig Dis; 2007 Nov 15; 8(4):211-5. PubMed ID: 17970879
    [Abstract] [Full Text] [Related]

  • 16. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
    Di Caro S, Franceschi F, Mariani A, Thompson F, Raimondo D, Masci E, Testoni A, La Rocca E, Gasbarrini A.
    Dig Liver Dis; 2009 Jul 15; 41(7):480-5. PubMed ID: 18974025
    [Abstract] [Full Text] [Related]

  • 17. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
    Wu IC, Wu DC, Hsu PI, Lu CY, Yu FJ, Wang TE, Chang WH, Chen JJ, Kuo FC, Wu JY, Wang WM, Bair MJ.
    Helicobacter; 2007 Dec 15; 12(6):633-7. PubMed ID: 18001406
    [Abstract] [Full Text] [Related]

  • 18. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection.
    Yee YK, Cheung TK, Chu KM, Chan CK, Fung J, Chan P, But D, Hung I, Chan AO, Yuen MF, Hsu A, Wong BC.
    Aliment Pharmacol Ther; 2007 Oct 01; 26(7):1063-7. PubMed ID: 17877513
    [Abstract] [Full Text] [Related]

  • 19. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
    Bago J, Pevec B, Tomić M, Marusić M, Bakula V, Bago P.
    Wien Klin Wochenschr; 2009 Oct 01; 121(1-2):47-52. PubMed ID: 19263014
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area.
    Matsuhisa T, Kawai T, Masaoka T, Suzuki H, Ito M, Kawamura Y, Tokunaga K, Suzuki M, Mine T, Takahashi S, Sakaki N.
    Helicobacter; 2006 Jun 01; 11(3):152-8. PubMed ID: 16684262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.